Skip to Main Content

Paper Details

Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.
Cancer Treat Rev
1
2023
BC, BCs, BMs, ERBB2 gene, HER2, HER2-positive BC, HER2-positive metastatic disease, HER2CLIMB, Tucatinib, advanced BC, brain metastases, breast cancers, capecitabine, human, human epidermal growth factor receptor 2, metastatic BC, patients, trastuzumab, tucatinib, tyrosine, tyrosine kinase
Author NameAffiliation
Carmen CriscitielloEuropean Institute of Oncology, IRCCS, University of Milan
Chiara CortiEuropean Institute of Oncology, IRCCS, University of Milan
Francesco DiMecoIstituto Nazionale Neurologico Carlo Besta
Giuseppe CuriglianoEuropean Institute of Oncology, IRCCS, University of Milan
  • 1 - 4

Datasets

Release 1.2